This finding suggests that the risk of severe neutropenia induced by irinotecan-based regimens cannot be predicted solely on the basis of UGT1A1 genotype and the administered dose of irinotecan; potential effects of other non-genetic factors such as patients' clinical characteristics must also be considered. This evidence concerns the gene UGT1A1 and Decreased total neutrophil count.